导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 10.08% | 825/4733 |
| 近一周 | -1.17% | 1738/5412 |
| 近一月 | -3.17% | 2217/5369 |
| 近一季 | -3.53% | 1629/5180 |
| 近半年 | 1.81% | 1113/4872 |
| 近一年 | 14.96% | 794/4367 |
| 近两年 | 84.74% | 785/2942 |
| 近三年 | 54.30% | 507/2242 |
| 成立以来 | 194.08% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.80% 1182/4961 |
16.27% 1585/5312 |
- - |
- - |
| 2025 | 32.71% 1165/4813 |
4.20% 980/3635 |
3.19% 1119/4076 |
21.29% 1819/4524 |
1.75% 1229/4813 |
| 2024 | 10.04% 1437/3463 |
-0.94% 1155/2808 |
-3.33% 1350/3014 |
15.62% 1672/3129 |
-0.61% 1480/3463 |
| 2023 | -5.84% 787/2656 |
5.61% 766/2280 |
-2.76% 654/2385 |
-4.64% 1190/2515 |
-3.86% 804/2655 |
| 2022 | -18.11% 664/2207 |
-9.72% 338/1919 |
3.27% 1183/2016 |
-11.79% 582/2113 |
-0.43% 1606/2208 |
| 2021 | 25.79% 108/1822 |
1.67% 247/1255 |
14.27% 260/1330 |
7.11% 195/1466 |
1.08% 1011/1822 |
| 2020 | 43.16% 253/1250 |
-1.80% 240/1028 |
19.01% 314/1067 |
17.25% 110/1164 |
4.47% 837/1184 |
| 2019 | 37.01% 345/1092 |
25.35% 472/739 |
-5.74% 477/788 |
7.46% 86/850 |
7.92% 381/918 |
| 2018 | - - |
- - |
- - |
- - |
-2.81% 21/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 国投瑞银中证500指数量化增强A VS. 长安沪深300非周期A(740101) |